Beryl Drugs raises Aminova related party transaction limit to ₹8 crore
- Beryl Drugs raised material RPT limit with Aminova Infusions to ₹8 crore
- Previous limit for related party transactions was ₹5 crore
- AGM adopted FY26 audited financial statements and reappointed Sudhir Sethi

*this image is generated using AI for illustrative purposes only.
Beryl Drugs Limited shareholders approved an increase in the limit for material related party transactions with Aminova Infusions Private Limited from ₹5.00 crore to ₹8.00 crore. This resolution was passed during the 33rd Annual General Meeting held on September 29, 2026.
The meeting also adopted the audited financial statements for the fiscal year ended March 31, 2026, and approved the reappointment of Sudhir Sethi as a director. The session took place at Kanchan Palace, Community Hall, Nipania Ring Road, Indore, commencing at 11:00 am and concluding at 11:30 am.
Key resolutions passed
The shareholders considered and approved three primary items on the agenda:
- Adoption of the audited financial statements, including the Balance Sheet, Statement of Profit & Loss, and Cash Flow statement for FY26.
- Reappointment of Sudhir Sethi (DIN: 00090172) as a retiring director.
- Increase in the limit of material related party transactions with Aminova Infusions Private Limited.
Details on related party transaction approval
The revised limit of ₹8.00 crore constitutes the overall ceiling for transactions covered under the existing approval granted by members at the Extraordinary General Meeting held on May 11, 2026. This increase applies to the unexpired period of that original approval, which had a tenure of two years.
The company clarified that this is not an additional ₹8.00 crore limit over and above transactions already undertaken pursuant to the earlier approval. All other terms and conditions, nature of transactions, and tenure parameters remain unchanged. The transactions continue to be undertaken in the ordinary course of business on an arm's length basis, subject to the Companies Act, 2013, and SEBI Listing Regulations.
Historical Stock Returns for Beryl Drugs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +6.15% | +6.23% | +10.78% | +37.99% | +13.40% | +76.32% |
What specific operational drivers or supply chain expansions prompted Beryl Drugs to increase its related party transaction limit with Aminova Infusions by 60%?
How might the increased reliance on Aminova Infusions impact Beryl Drugs' negotiating leverage and cost structure in future procurement cycles?
Will the higher transaction ceiling lead to increased scrutiny from SEBI regarding the arm's length pricing of these related party deals?


































